Title : As Maintenance Therapy, Olaparib's Benefits Continue.

Pub. Date : 2022 Jan

PMID : 34799380






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 A 5-year follow-up of patients in the ongoing SOLO1 trial showed that patients with advanced BRCA-mutated ovarian cancer who had finished platinum-based chemotherapy had a significantly longer median progression-free survival when they received 2 years of olaparib as a maintenance therapy instead of placebo-56 months versus 13.8 months, respectively. Platinum BRCA1 DNA repair associated Homo sapiens